Spruce Biosciences (SPRB) Stock Price, News, Quotes-Moomoo

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Spruce Biosciences Appoints Interim Chief Medical Officer
TipRanksDec 27 17:49 ET
H.C. Wainwright Maintains Spruce Biosciences(SPRB.US) With Hold Rating
Moomoo NewsDec 16 07:31 ET · Ratings
Spruce Biosciences (SPRB) Upgraded to Buy: Here's Why
Zacks Dec 13 11:15 ET
Express News | Guggenheim Reiterates Neutral on Spruce Biosciencesto Neutral
BenzingaDec 12 10:38 ET
Spruce Biosciences Faces Setbacks With Tildacerfont Program, Hold Rating Maintained
TipRanksDec 12 02:06 ET
Spruce Biosciences Cut to Market Perform From Market Outperform by JMP Securities
Dow JonesDec 11 12:40 ET · Ratings

Comments

Jaguar8

Dec 10 15:01

NEWS

$Spruce Biosciences (SPRB.US)$
Spruce Biosciences Announces Topline Results from CAHmelia-204 in Adult CAH and CAHptain-205 in Adult and Pediatric CAH
Tuesday, 10th December at 4:01 pm
CAHmelia-204 Study of 200mg Once-Daily (QD) Tildacerfont in Adult Congenital Adrenal Hyperplasia (CAH) Did Not Achieve Primary Endpoint of Glucocorticoid (GC) Reduction
Dose-Ranging Data from CAHptain-205 Study of Tildacerfont in Adult and Pediatric CAH Suggests Higher Doses and Twice-Daily (BID) Dosing May Be ...

73372627

Aug 10 13:31

$Zebra Technologies (ZBRA.US)$ and the true of the Spruce analysis

I will never undestend why this company is not investigated for manipulating the market on theirs own interest.
Let's go see why such investigation is neccessary and I hope Zebra will complain.
Spruce it is an Short-selling company which allways made negative reports or analysis in order to influence the market for theyr's own profit. Parallel with Short-selling they are also in real estate managment in New York where they loose b...

8

1

Jaguar8

Jun 4 06:13

NEWS

$Spruce Biosciences (SPRB.US)$
Spruce Biosciences and HMNC Brain Health Announce Strategic Collaboration to Develop Treatment for Major Depressive Disorder (MDD)
Spruce Biosciences (Nasdaq: SPRB) and HMNC Brain Health announced a strategic collaboration to develop a treatment for Major Depressive Disorder (MDD) using Spruce's tildacerfont and HMNC's Cortibon Genetic Selection Tool. The Phase 2 study is set to begin in Q4 2024. Should the study be successful, Spruce has the option to acquire e...

1